Measles Cases Surge as Vaccination Rates Drop, Sparking Urgent Search for Antiviral Treatments
Measles cases in the United States have reached their highest level in over three decades, with 2,030 reported cases as of June 4, 2025—a stark increase from previous years. The rise, driven by declining vaccination rates, has intensified calls for antiviral treatments, as current medical care focuses on symptom management rather than direct viral suppression.
Why Are Measles Cases Rising Despite a Vaccine?
The measles vaccine, which prevents 97% of cases with two doses, has long been a public health triumph. However, global vaccination rates have fallen below 95% in many regions, creating vulnerabilities. In the U.S., 90% of 2025 cases occurred in unvaccinated individuals or those with unknown status, according to the CDC. Factors include vaccine hesitancy fueled by misinformation, gaps in healthcare access, and funding cuts to global immunization programs.
“Vaccines have been so successful that we’ve neglected the need for antivirals,” said Ruth Lynfield, an epidemiologist at the Minnesota Department of Health. “Now, with rising cases, that gap is becoming critical.”
What Makes Measles So Dangerous?
Measles is not just a childhood illness; it can lead to severe complications, including pneumonia, blindness, and encephalitis. The virus also weakens the immune system, leaving survivors susceptible to other infections. About 1 in 1,000 infected individuals develop encephalitis, and 1 to 3 children die per 1,000 cases, according to the CDC.
“Measles is far more than a rash—it’s a systemic threat,” said Kathryn Hastie, a structural virologist at the La Jolla Institute for Immunology. “The misconception that it’s ‘not that bad’ underestimates its long-term risks.”
What Research Is Being Done on Measles Antivirals?
Two promising approaches are under investigation: repurposed drugs and monoclonal antibodies. Richard Plemper, a virologist at Georgia State University, is testing GHP-88310, a compound that inhibits viral replication. In ferret studies, the drug reduced measles-like infections and prevented death when administered three days post-exposure.
Meanwhile, Hastie’s team identified human-derived monoclonal antibodies that neutralized measles in cotton rats. One antibody eliminated the virus entirely, raising hopes for rapid post-exposure treatments. Unlike vaccines, which take weeks to build immunity, these antibodies could offer immediate protection.
How Do Clinical Trials for Measles Treatments Work?
Conducting trials for measles antivirals is challenging due to the virus’s declining prevalence in high-income countries. “We need outbreaks to test treatments, but that’s ethically complicated,” Plemper said. Researchers are instead studying related viruses, such as human parainfluenza virus, to validate drug candidates before human trials.
Funding remains a barrier. While U.S. biotech firms are exploring monoclonal antibodies, global efforts face hurdles in reaching populations with limited vaccine access. “Without investment, we’ll be unprepared for the next outbreak,” Lynfield warned.
What’s the Path Forward for Measles Control?
Experts agree that vaccination remains the most effective strategy. However, antivirals could serve as a critical backup for unvaccinated individuals, immunocompromised patients, and those exposed during outbreaks. Plemper emphasized, “Vaccines are our first line of defense, but we need alternatives to fully eliminate the virus.”
As cases climb, the race to develop measles antivirals underscores a broader lesson: even diseases deemed “controlled” require ongoing innovation. “Success can blind us to future risks,” Hastie said. “Measles is a reminder that preparedness must keep pace with progress.”
For more on measles prevention and treatment, visit the CDC’s measles page.